• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Med Hypotheses. Etoposide-based therapy for severe forms of COVID-19

tetano

Editor, Senior Moderator
Med Hypotheses. 2020 May 8;142:109826. doi: 10.1016/j.mehy.2020.109826. [Epub ahead of print]
Etoposide-based therapy for severe forms of COVID-19.


Hamizi K[SUP]1[/SUP], Aouidane S[SUP]2[/SUP], Belaaloui G[SUP]3[/SUP].

Author information




Abstract

The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.
Copyright ? 2020 Elsevier Ltd. All rights reserved.



KEYWORDS:

COVID-19; Etoposide; HLH; Haemophagocytic lymphohistiocytosis


PMID:32416415DOI:10.1016/j.mehy.2020.109826
 
Back
Top Bottom